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ABSTRACT
The p53 cancer mutant Y220C is an excellent
paradigm for rescuing the function of conform-
ationally unstable p53 mutants because it has a
unique surface crevice that can be targeted by
small-molecule stabilizers. Here, we have identified
a compound, PK7088, which is active in vitro:
PK7088 bound to the mutant with a dissociation
constant of 140 kM and raised its melting tempera-
ture, and we have determined the binding mode of a
close structural analogue by X-ray crystallography.
We showed that PK7088 is biologically active
in cancer cells carrying the Y220C mutant by
a battery of tests. PK7088 increased the amount of
folded mutant protein with wild-type conformation,
as monitored by immunofluorescence, and restored
its transcriptional functions. It induced p53-Y220C-
dependent growth inhibition, cell-cycle arrest and
apoptosis. Most notably, PK7088 increased the ex-
pression levels of p21 and the proapoptotic NOXA
protein. PK7088 worked synergistically with Nutlin-3
on up-regulating p21 expression, whereas Nutlin-3 on
its own had no effect, consistent with its mechanism
of action. PK7088 also restored non-transcriptional
apoptotic functions of p53 by triggering nuclear
export of BAX to the mitochondria. We suggest a
set of criteria for assigning activation of p53.
INTRODUCTION
The tumour suppressor p53 is a centrepiece in the cell’s
defence against cancer (1). p53 is activated in response to
cellular stresses and initiates a variety of cellular responses
including cell cycle arrest and apoptosis (2,3). It is
inactivated by mutation in many cancers, and loss of
p53 function can lead to more aggressive cancer forms
(4) or resistance to chemotherapy (5). Most p53 mutations
are missense mutations in its DNA-binding (also called
core) domain, which can be divided into two classes:
contact mutations that interfere with p53-DNA contacts,
and structural mutations that destabilize the protein,
causing it to unfold and aggregate rapidly at physiological
conditions (6). Analysis of the p53 mutation database of
the International Agency for Research on Cancer (7)
suggests that about 30–40% of p53 cancer mutations are
structural mutations (8). In principle, temperature-sensi-
tive destabilized structural mutants that are functional at
low temperature but denature at higher temperatures may
be rescued by small molecules that bind to the native state
of p53 and stabilize it (9,10). Y220C is the ninth most
frequent p53 cancer mutation and destabilizes the p53
core domain by about 4 kcal/mol, with the protein
>80% unfolded at body temperature (10,11). Y220C is
an ideal test case for a small-molecule stabilization
approach because the tyrosine-to-cysteine mutation
creates a unique surface crevice that is druggable. We
have recently developed two classes of small molecules,
substituted 9-ethylcarbazoles (12) and 2-(aminomethyl)-
4-ethynyl-6-iodophenols (13), the latter featuring an
iodine-oxygen halogen bond as core interaction.
Attempts to identify p53-activating compounds have
been made from antibody assays and cell-based screening
(14). The ﬁrst of these compounds, CP-31398, (15) was
reported to stabilize the p53 core domain and be active
against cancer xenografts. But, it was later shown using
direct biophysical techniques that CP-31398 does not bind
to the p53 core domain, does not stabilize p53 in vitro but
is a DNA intercalator (16) and is toxic to cell lines H1299
and Saos-2, which are commonly used to test p53 activity
(17). It is our experience in conducting many cell-based
assays that there is a large number of false positives for the
reactivation of p53 mutants that somehow result from
more general effects of cytotoxicity or more speciﬁc
effects that appear to manifest themselves as p53
reactivation.
Here, we have combined biophysical and cell-based
techniques to identify and characterize a new compound,
PK7088. This compound has been identiﬁed from an in-
house synthesized fragment library (18–23), binds to the
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p53 Y220C core domain and, most importantly, reacti-
vates cellular p53 functions in p53-Y220C mutant cells.
MATERIALS AND METHODS
Protein NMR spectroscopy
1H/15N-heteronuclear single quantum coherence (HSQC)
spectra of uniformly 15N-labelled T-p53-Y220C (75 mM)
with and without PK7088 were acquired at 20C on a
Bruker Avance-800 spectrometer using a 5-mm inverse
cryogenic probe. Samples were prepared by adding dilu-
tions of compound from stock solutions in DMSO-d6 to a
ﬁnal concentration of 5% (v/v) DMSO-d6 in buffer. All
HSQC spectra were acquired with 8 transients per t1 data
point, 1024 data points in t2, and 64 complex data points
in t1, with spectral widths of 11.0 kHz for
1H and 2.7 kHz
for 15N, and a recycle delay of 800ms. Chemical shifts
were considered signiﬁcant if the average weighted
1H/15N chemical shift difference
ð1H=15NÞ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðð1HÞÞ2+ðð15NÞ=5Þ2
q
was greater
than 0.04 ppm. To determine dissociation constants, at
least ﬁve 15N/1H HSQC spectra at different compound
concentrations were measured. Spectra analysis was per-
formed using Sparky 3.114 (24) and Bruker Topspin 2.0
software. To derive KD values, a quadratic saturation
binding equation was ﬁtted to the concentration-depend-
ent chemical shift changes of the relevant shifting peaks:
@obs¼ @max
½L0+½P0+KD
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð½L0+½P0+KDÞ24  ½P0  ½L0
q
2  ½P0
Differential Scanning Fluorimetry (DSF)
The effect of PK7088 on the melting temperature of T-
p53C-Y220C was measured using SYPRO Orange as
described previously (11). PK7088 was added to the
protein at a range of concentrations (75, 150, 250 and
350 mM).
X-ray crystallography
Crystals of T-p53C-Y220C were grown as described pre-
viously (11). They were soaked for 3 h in a 40mM solution
of compound PK7242 in 19% polyethylene glycol 4000,
20% glycerol, 10mM sodium phosphate, pH 7.2, 100mM
HEPES, pH 7.2, 150mM KCl and 10mM dithiothreitol
(DTT), and ﬂash frozen in liquid nitrogen. An X-ray data
set was collected at 100K on beamline I02 at the Diamond
Light Source, Oxford. The data set was processed with
XDS (25) and SCALA (26). The structure was solved by
rigid body reﬁnement with PHENIX (27) using the struc-
ture of the ligand-free mutant (PDB ID 2J1X) as a starting
model. Iterative model building and reﬁnement was done
using Coot (28) and PHENIX. Data collection and reﬁne-
ment statistics are shown in Supplementary Table S2. The
atomic coordinates and structure factors of the Y220C-
PK7242 complex have been deposited in the Protein
Data Bank, www.pdb.org (PDB ID code 3ZME).
Structural ﬁgures were prepared using PyMOL (www.
pymol.org).
Cell culture
HUH-7 (p53-Y220C+/+, registration no. JCRB0822),
HUH-6 (wild-type p53+/+, registration no. JCRB0834),
NUGC-3 (p53-Y220C+/+, registration no. JCRB0401),
NUGC-4 (wild-type p53+/+, registration no. JCRB0403)
and MKN-1 (p53-V143A+/+, registration no. JCRB0252)
cells were purchased from Japan Health Science Research
Resources Bank. HUH-7 and HUH-6 cells were main-
tained in DMEM medium with 10% fetal calf serum
and 1% antibiotic stock mix (10 000U/ml penicillin,
10 000 mg/ml streptomycin), and other cell lines were main-
tained in RPMI1640 medium with the same concentration
of serum and antibiotics. All cells were incubated in a
humidiﬁed incubator at 37C with 5% CO2.
Cell viability assay
Cell viability was monitored by crystal violet staining.
Brieﬂy, 1 105 cells were seeded per well in 6-well
plates. After 24-h treatment, cells were washed with PBS
and ﬁxed using 50:50 methanol/acetone solution (v/v).
Cells were then stained with crystal violet (0.2% w/v in
2% ethanol) for 30min, washed with PBS and dried at
room temperature.
Caspase-3/7 assay
Activity of caspase 3/7 was measured using a Caspase-Glo
3/7 assay kit (Promega G8091), following the manufac-
turer’s instructions. PRIMA-1MET was purchased from
Santa Cruz Biotechnology.
p53 knockdown by siRNA
Silencing of p53 was achieved by transfection of human-
speciﬁc p53 siRNA (Cell Signaling Technology) using the
RiboJuice siRNA Transfection Reagent (Novagen).
Downregulation of p53 expression was conﬁrmed by
western blots.
Cell cycle analysis
Cells were treated for 6 h, collected and re-suspended in
0.4ml hypotonic ﬂuorochrome solution and analysed with
an Eclipse Flow Cytometry Analyzer. Nutlin3 was
purchased from Tocris Bioscience.
Annexin V/PI staining
AnnexinV/propidium iodide (PI) staining was used to de-
termine the percentage of apoptotic cells after treatment
for 24 h. The pan-caspase inhibitor Z-Val-Ala-Asp-
(OMe)-CH2F (Z-VAD-fmk, Sigma) was used at a concen-
tration of 50 mM. Sample preparation, staining and
analysis were performed following the protocol provided
by BD Bioscience.
Western blots
Western blotting was performed as described (29).
The following antibodies were used: p53 Do-7 (Dako),
p21 (Millipore), Puma (Abcam), Noxa (Abcam),
MDM2 (Abcam), Bax (Cell Signalling Technologies),
b-actin (Abcam). Both anti-mouse and anti-rabbit
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immunoglobulin G (IgG) horseradish peroxidase-
conjugated antibodies were obtained from Dako.
Real-Time PCR
HUH-7 cells were treated with 200 mM PK7088 or DMSO
control for 6 h. RNA was extracted and puriﬁed using
RNeasy Mini Kit (QIAGEN) and RNase-Free DNase
Set (QIAGEN). cDNA reverse transcription was per-
formed using High Capacity RNA-to-cDNA Kit
(Applied Biosystems). Twenty nanogram cDNA and
10 ml of TaqMan Gene Expression Master Mix (Applied
Biosystems) were added to each well of a TaqMan Human
Cellular apoptosis Pathway plate (Applied Biosystems).
The thermal-cycling conditions were set according to the
manufacturer’s instructions, and reactions were performed
using a ViiATM 7 Real-Time PCR System (Applied
Biosystems). The comparative threshold cycle (Ct)
method was used to analyse the gene expression levels.
Immunoﬂuorescence
Cells were treated with 200 mM PK7088 or DMSO control
for 4 h or 6 h, ﬁxed and permeabilized using 50:50
methanol/acetone solution (v:v). The following antibodies
were used: anti-p53 antibody Pab 1620 (Abcam), anti-p53
antibody Pab 240 (Abcam), anti-Bax (Cell signalling) and
goat Pab to Ms Dylight 488 (Abcam). Hoechst 33342 (cell
signalling) and MitoTracker Red CMxRos (Lonza) were
used to stain the nucleus and mitochondria of cells.
Imaging was performed using a Zeiss710 system.
RESULTS
PK7088 binds and stabilizes the Y220C mutant
The small molecule 1-methyl-4-phenyl-3 -(1H-pyrrol-1-yl)-
1H-pyrazole (PK7088, Figure 1A) was identiﬁed as a
Y220C binder by protein-observed NMR screening and
binds to this mutant with KD=140 mM as determined by
chemical shift mapping using 1H/15N-HSQC NMR spec-
troscopy (Figure 1C and D). It also stabilizes p53-Y220C
core domain by 1K at 350 mM compound concentration
(Figure 1B). Attempts to solve the crystal structure of the
Y220C–PK7088 complex failed because of the relatively
poor solubility of the molecule. We designed, therefore, a
more soluble derivative of PK7088, PK7242, by adding an
N,N-dimethyl-ethanamine linker (Figure 1E). 1H/15N-
HSQC spectra of p53-Y220C core domain in the presence
of PK7088 or PK7242 were virtually identical, indicating
that both compounds have the same overall binding mode
(Supplementary Figure S1). Compound PK7242 was
soaked into Y220C crystals, and the crystal structure of
the complex was solved at 1.35 A˚ resolution, with excellent
electron density for the ligand. The binding mode is shown
in Figure 1F. Binding of PK7242 is accompanied by a ﬂip
of the Cys220 side chain, which increases the depth of the
cavity to accommodate the pyrrole moiety. The central
pyrazole ring is sandwiched between Val147, Thr150 and
Pro151 on one side and Pro222 and Pro223 on the other
side of the pocket. It forms a hydrogen bond with a struc-
tural water molecule stabilized by the backbones of Leu145
and Thr230. The ﬂuorophenyl moiety points toward a
subsite that was previously targeted via an acetylene
linker (13). The N,N-dimethyl-ethanamine linker, added
to increase the solubility of the compound, is solvent-
exposed.
PK7088 induces caspase-3/7 selectively in
p53-Y220C cells
Apoptotic effects of PK7088 on three gastric cancer cell
lines (NUGC-3, NUGC-4 and MKN-1) and two human
hepatoblastoma cell lines (HUH-6 and HUH-7) were
determined by induction of caspase-3/7 after 6 h PK7088
treatment at different concentrations (Figure 2). These cell
lines were chosen because they have a different p53 status
with homozygous p53 gene (Y220C, V143A or wild-type).
Compared with DMSO control, PK7088 induced caspase-
3/7 signiﬁcantly at 200 mM in the Y220C-containing
NUGC-3 and HUH-7 cells, while only small effects were
observed in p53 wild-type (NUGC-4, HUH-6) and V143A
mutant (MKN-1) cells. We also studied the effects of
Prima-1MET, a reported mutant p53 reactivator, on
caspase induction (Figure 2B). At 25 mM compound con-
centration, Prima-1MET increased caspase-3/7 activity only
in MKN-1 cells. On treatment with 100 mM Prima-1MET,
induction of caspase-3/7 was also observed in NUGC-4
cells, whereas Prima-1MET had no effect in p53-Y220C cell
lines at the concentrations tested.
PK7088 restores wild-type p53 conformation in
p53-Y220C cells
To investigate whether PK7088 stabilizes the Y220C
mutant in cancer cells and increases the amount of cor-
rectly folded p53 protein, we performed immunoﬂuores-
cence assays using two conformation-speciﬁc antibodies,
PAb240 and PAb1620, after 4 h incubation with the small
molecule. The PAb240 antibody recognizes an epitope
that is buried in the hydrophobic core of the protein (i.e.
it can only bind to unfolded p53) (30,31), whereas
PAb1620 binds an epitope on the surface of correctly
folded p53 (32). In HUH-7 cells, PK7088 signiﬁcantly
increased the amount of folded Y220C mutant, as
detected with Pab1620, showing a 76% increase in ﬂuor-
escence intensity compared with untreated cells after nor-
malization. In contrast, the ﬂuorescence intensity of
antibody PAb240 (detecting unfolded protein) was
decreased to 38% of that in untreated cells, suggesting
an almost 3-fold reduction in the amount of unfolded
mutant (Figure 3A and Supplementary Figure S2). In
addition, the folded protein was found mainly in the
nucleus, while mutant p53 was observed both inside and
outside the nucleus of untreated HUH-7 cells. In contrast,
PK7088 had no effect on the folding state of p53 in V143A
mutant MKN-1 cells (Figure 3B).
PK7088 induces p53-Y220C-dependent cell cycle and
apoptotic effects
p53 silencing was performed in HUH-7 cells to conﬁrm
the p53-Y220C-speciﬁc effects of PK7088. The MDM2
antagonist Nutlin-3, which activates the p53 pathway in
p53 wild-type cells, was used to conﬁrm restoration of p53
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function after PK7088 treatment. In HUH-7 cells, p53
knockdown or Nutlin-3 (10 mM) had no notable effect
on the cell cycle (Figure 4A). Incubation with 200 mM
PK7088 for 6 h caused G2/M cell-cycle arrest, which was
increased further when combined with treatment with
10 mM Nutlin-3. In p53-silenced HUH-7 cells, the
percentage of cells arrested in the G2/M phase was
reduced considerably from 42% to 32%. In contrast,
PK7088 did not induce G2/M arrest in HUH-6 cells.
To study further the p53-Y220C-dependent cell-cycle
effect of PK7088, we determined the protein level of the
p53 target gene p21 by western blotting (Figure 4B).
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Figure 1. Biophysical and structural characterization of PK7088 binding to p53-Y220C. (A) Chemical formula of PK7088. (B) Concentration-
dependent thermostabilization of the Y220C mutant by PK7088 measured by DSF. (C) Overlay of 1H/15N-HSQC NMR spectra of p53-Y220C
core domain (94-312) with varying concentrations of PK7088. (D) Quadratic saturation binding equation ﬁtted to the concentration-dependent
chemical shift changes of the relevant shifting peaks yields a KD& 140mM. (E) Chemical formula of PK7242, a more soluble analogue of PK7088
that was used for crystallography. (F) Crystal structure of p53-Y220C core domain in complex with PK7242. The binding pocket is depicted as a grey
ribbon diagram, with selected side chains shown as stick models. PK7242 is shown as a green stick model. The interaction of the central pyrazole
moiety with a network of structural water molecules is highlighted with broken lines.
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PK7088 induced p21 expression after 6-h treatment in
HUH-7 but not HUH-6 cells. As expected, Nutlin-3
increased p21 only in p53 wild-type HUH-6 cells but did
not change the p21 level in mutant HUH-7 cells. In the
presence of PK7088, Nutlin-3 enhanced the up-regulation
of p21 only in HUH-7 cells but not in HUH-6 cells.
The cytotoxic and apoptotic effects of PK7088
were determined by crystal violet (Figure 4C) and
AnnexinV/PI staining (Figure 4D), respectively. PK7088
reduced the cell viability of HUH-7 cells at 100 mM after
24-h treatment, whereas p53-silenced cells were less sensi-
tive to PK7088. In HUH-7 cells, induction of apoptosis
was detected after 24-h incubation with 200 mM PK7088.
p53 knockdown reduced the cell death caused by PK7088.
In the presence of the pan-caspase inhibitor Z-VAD-fmk
(50 mM), the apoptotic effect of PK7088 was largely
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Figure 2. Induction of caspase 3/7 by PK7088 or PRIMA-1. PK7088 activates caspase 3/7 selectively in p53-Y220C mutant cells (A), while PRIMA-
1 induced caspase in p53-V143A mutant cells and p53 wild-type cells (B). Induction of caspase 3/7 activity was determined after 6-h PK7088
treatment in ﬁve cell lines with different p53 status, including the Y220C mutant (NUGC-3, HUH-7), the V143A mutant (MKN-1) and wild-type p53
(NUGC-4, HUH-6).
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inhibited. HUH-6 cells were insensitive to PK7088 at the
tested ligand concentrations.
PK7088 induces NOXA and regulates Bax relocation
The mRNA levels of p53, MDM2 and the pro-apoptotic
proteins Bax, NOXA and PUMA in HUH-7 cells were
measured by real time PCR after 6-h incubation with
200 mM PK7088 (Figure 5A). NOXA and PUMA
mRNA levels were increased 1.9- and 2.6-fold, respect-
ively, while the mRNA levels of MDM2 and Bax
remained unchanged. As shown in Figure 5B, western
blots conﬁrmed that the majority of p53 was knocked
down by siRNA, and PK7088 increased the expression
of NOXA in a p53-dependent manner. Nutlin-3 alone
had no effect on NOXA expression, but it further
increased NOXA expression in the presence of PK7088.
Little effect was observed on MDM2, PUMA or Bax
protein levels. Interestingly, we observed p53-dependent
relocation of Bax to the mitochondria after treating
HUH-7 cells for 6 h with 200 mM PK7088 (Figure 6A).
Hoechst dye (blue) was used to visualize the location of
the nucleus, while the mitochondria of HUH-7 cells were
stained with MitoTracker dye (red). In untreated HUH-7
cells, Bax was located mainly in the nucleus, whereas
PK7088 seemed to induce the translocation of Bax from
the nucleus to the mitochondria. In HUH-7 cells where
p53 had been knocked down, the relocation of Bax was
inconspicuous compared with un-silenced cells. In
addition, the distribution of Bax was unaffected in wild-
type HUH-6 cells (Figure 6B).
PK7088 does not inhibit a range of cancer kinases
To rule out off-target kinase inhibitory effects
contributing to the cellular activity of PK7088, we
screened this compound as well as its demethylated
analogue PK7209, which does not stabilize Y220C,
against a panel of 74 cancer kinases at a concentration
of 50 mM. No signiﬁcant effects were observed
(Supplementary Table S1). Also, PK7088 does not
inhibit b-raf kinase although its chemical structure resem-
bles that of some reported b-raf inhibitors (33).
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Figure 3. Effect of PK7088 on the folding state of p53 in different cancer cell lines. PK7088 increased the amount of correctly folded p53 while
decreasing the amount of unfolded p53 in HUH-7 (p53-Y220C) cells but not MKN-1 (p53-V143A) cells. Immunostaining of HUH-7 cells (A) and
MKN-1 cells (B) was performed using the conformation-speciﬁc antibodies Pab1620 (wild-type/folded) and Pab240 (mutant/unfolded). Both cell lines
were treated with DMSO control or 200 mM PK7088 for 4 h. Hoechst 33342 dye was used to stain the nucleus.
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DISCUSSION
With its unique surface crevice, the p53 cancer mutant
Y220C is an excellent test case for the development of
p53 rescue drugs. We have previously developed different
classes of small-molecule stabilizers of this mutant and
extensively analysed their binding mode and their effect
on melting temperature and aggregation properties
(12,13,34,35). Here, we have discovered a new class of
compounds based on a substituted 4-phenyl-3-(1H-
pyrrol-1-yl)-1H-pyrazole scaffold and determined the
binding mode of a representative member of this
compound class by X-ray crystallography, revealing key
interactions with the Y220C-speciﬁc binding pocket.
The most interesting aspect of the small molecule PK7088,
which has a moderate binding constant of 140mM in vitro, is
its potency in cancer cell lines carrying the Y220C mutation.
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Figure 4. Y220C mutant-speciﬁc cell-cycle and apoptotic effects of PK7088. (A) FACS analysis of HUH-7 and HUH-6 cells after 6-h incubation
with 200mM PK7088. PK7088 induced p53-dependent G2/M phase arrest in HUH-7 cells, which was enhanced by Nutlin-3. (B) Protein levels of the
p53 target gene p21 detected by western blots after 6-h treatment. PK7088 induced p21 in HUH-7 cells but not HUH-6 cells. Nutlin-3 induced p21 in
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AnnexinV/PI staining. In HUH-7 cells, 200mM PK7088 induced apoptosis, which was counteracted by p53 knockdown. No cell death was detected
in HUH-6 cells. The pan-caspase inhibitor Z-VAD-fmk (50 mM) blocked the cell death effect induced by PK7088.
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Our immunoﬂuorescence assays using the p53-conform-
ation-speciﬁc antibodies PAb1620 and PAb240 to monitor
the folding state of p53 clearly showed that PK7088 signiﬁ-
cantly increases the amount of correctly folded p53 in HUH-
7 cells, thus potentially restoring p53 function. Consistent
with the proposed mechanism of action of PK7088 as
mutant-speciﬁc small-molecule stabilizer, no effect on the
levels of folded p53 protein was observed in cancer cell
lines with V143A mutation. A similar increase in the
amount of folded mutant protein in a cancer cell line
induced by a small molecule was recently reported for the
structural mutant R175H which, like Y220C, is normally
largely unfolded at body temperature (36). Given the struc-
ture of the Y220C mutant (11) and its reported temperature-
sensitive phenotype (37,38), an increase in the amount of
folded protein in the HUH-7 cancer cells should result in
the up-regulation of p53 target genes. Indeed, we observed
up-regulation of various p53 downstream targets both at the
mRNA and protein level upon PK7088 treatment in a
mutant-speciﬁc manner, affecting both cell-cycle arrest and
apoptotic functions.
To assess the cell-cycle arrest function of p53, we moni-
tored the protein levels of the transcriptional target p21,
which inhibits cyclin-dependent kinases (CDKs) and
causes cell-cycle arrest. Up-regulation of p21 by a tetracyc-
line-regulated system, for example, induces G2 arrest in
many cell lines, including Hela, Saos-2, U2OS and H1299
(39). We found that PK7088 induces p21- and p53-depend-
ent G2/M arrest in p53-Y220C cells but not p53 wild-type
cells, suggesting restoration of wild-type p53 function of the
Y220C mutant in the HUH-7 cells. Interestingly, PK7088
acted synergistically with Nutlin-3. Nutlin-3 mimics the
transactivation domain of p53 and competes with binding
of the latter to the N-terminal domain of MDM2, thereby
inhibiting MDM2-mediated degradation of p53 (40).
Nutlin-3-induced effects, such as cell-cycle arrest and induc-
tion of apoptosis, are therefore generally only observed in
cancer cell lines with wild-type p53, but not in cells that
carry inactive mutant p53 (41–43). As expected, Nutlin-3
had no effect on HUH-7 cells in the absence of PK7088.
When combined with PK7088 treatment, however, Nutlin-
3 increased p21 expression and G2/M arrest of HUH-7
cells, indicating levels of active p53 that are further up-
regulated through inhibition of one of its degradation
pathways.
In addition to the above effects on cell-cycle arrest, we
observed several apoptosis-related events upon PK7088
treatment that were speciﬁc to HUH-7 (p53-Y220C)
cancer cells. As part of the p53-mediated apoptotic
process, caspases undergo proteolytic activation (44).
Apoptosis and caspase 3/7 activity were induced selectively
in p53-Y220C HUH-7 cells upon treatment with 200 uM
PK7088. This induction of apoptosis was inhibited by
addition of pan caspase inhibitor Z-VAD-fmk, indicating
that PK7088 triggers apoptosis in a p53-Y220C- and
caspase-dependent manner. We also observed up-regulation
of mRNA levels of the p53 downstream targets PUMA and
NOXA, two critical mediators of the p53-induced apoptotic
responses (45,46), after 6-h incubation with PK7088.
NOXA protein levels were also increased whereas no
effect on the protein levels of PUMA was observed.
Importantly, both mRNA and total p53 protein level were
unchanged, indicating that PK7088 works by increasing the
ratio of correctly folded Y220C mutant at a given expres-
sion level. PK7088 binds non-covalently to Y220C and acts
in an entirely different way from Prima-1MET, which binds
covalently to the p53 core domain via alkylation of cysteine
residues (47), which affects DNA binding (48). Accordingly,
the precise reactivation mechanism of mutant p53 by
Prima-1MET is different from that of 7088.
p53 can promote apoptosis through transcription-inde-
pendent mechanisms (49,50). The crucial step of the tran-
scription-independent pathway in p53-mediated apoptosis
is the stress-induced accumulation of p53 in the cytosol or
mitochondria, leading to activation of Bax or Bak (3,49).
During apoptosis, Bax is translocated from the cytosol to
mitochondria where it triggers mitochondrial outer
membrane permeabilization (51), and wild-type p53 was
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Figure 5. Restoration of wild-type p53 functions in HUH-7 cells by
PK7088. (A) mRNA levels of p53 target genes measured by real-time
PCR after 6-h treatment. 200mm PK7088 up-regulated NOXA
and PUMA mRNA, but had no effect on p53, MDM2 or Bax.
(B) Protein levels of p53 target genes determined by western blots.
PK7088 induced dose-dependent up-regulation of NOXA protein,
whereas PUMA or Bax levels were unaffected.
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reported to activate Bax directly (52) and induce a con-
formational change in Bax (53). Intriguingly, we observed
translocation of folded p53 from the nucleus to the cyto-
plasm after 4-h treatment with PK7088 in HUH-7 cells.
The mRNA and protein levels of Bax were unaffected by
PK7088, but PK7088-induced relocation of Bax to the
mitochondria was observed, which was prevented by p53
knockdown, providing further evidence that PK7088
restores various aspects of p53 function.
Criteria for reactivation of p53 in cell lines
As we have found several molecules that induced the p53
target gene p21 in cell-based screening assays but showed
no detectable binding to Y220C in vitro, we suggest the use
of the following criteria to screen for genuine p53 reacti-
vation: direct demonstration of binding to the mutant
protein and its thermal stabilization; visualization in cell
lines that p53 is restored to its folded state in cells by using
antibodies such as PAb1620 and PAb240; and activation
of p53 target genes such as p21 that is abolished on p53
knockdown, or equivalent mutant-speciﬁc induction in
isogenic cell lines differing only in p53 mutation status.
p53-dependent synergistic effects of inhibitors of MDM2
on transcription provide further evidence.
In fulﬁlling all these criteria, we have proven in this
study that PK7088 is a mutant-speciﬁc p53-Y220C stabil-
izer. Future structure-guided optimization of the current
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Figure 6. Effect of PK7088 on the cellular localization of Bax. PK7088 induced relocation of Bax to the mitochondria in HUH-7 cells (A), but not in
HUH-6 cells (B) after 6-h treatment at 200 mm. Nucleus and mitochondria were stained with Hoechst 33342 and MitoTracker Red CMxRos dye,
respectively.
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lead should increase its afﬁnity to the Y220C mutant and
further improve its selectivity in cancer cells.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–2 and Supplementary Figures
1–2.
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